Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.11.18 (MAP)
 7,412 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

On the basis of previous observations indicating that Medroxyprogesterone Acetate (MAP) administered in high doses induces leukocytosis and an increase in the platelet count, the Authors have studied the effect of high-dose MAP on leukocytes and platelets when it was combined with Chlorambucil (CLB) in patients suffering from ovarian cancer in various stages. 28 patients treated with high-dose MAP and CLB showed a statistically significant lower mean reduction of WBC count and reduction of the incidence, entity, and duration of the leukopenia as compared to 29 patients treated only with CLB. These effects were particularly evident when MAP was administered intramuscularly. It was not possible to evaluate the effect of high-dose MAP on the platelet count because the CLB regimen did not induce a significant decrease in it. These preliminary results are interesting because they suggest the possibility that high-dose MAP, which has already been utilized in oncology for its antitumor, analgesic, and anabolic activity in the treatment of breast, endometrial, renal, and prostatic cancer, might be able to be employed to reduce the myelotoxic effects of chemotherapy.
 ...
PMID:[Effect of medroxyprogesterone acetate (MAP) in high doses on chlorambucil-induced bone marrow depression. Preliminary results]. 622 Jun 86

On the basis of a personal series of 43 cases of ovarian endometrioid carcinoma the Authors point out that this histologic type is more hormonosensitive than the other ovarian carcinomas. Their search for ER and PgR receptors in the tumour tissue showed a particularly high incidence of positive cases (81.3% and 72.1% respectively). Furthermore, the adjuvant, high-dose MAP therapy (Farlutal) obtained a high incidence of positive responses with neoplastic regression in 53.5% of the patients, all of whom were PgR-and/or ER-positive cases. 71.2% of the cases that could be followed survived at 3 years and 57.1% survived at 5 years from the beginning of the therapy. From this standpoint too, the Authors compare ovarian endometrioid carcinoma to endometrial carcinoma and believe that the determination of estrogen and progesterone receptors in the neoplastic tissue can apply to the former too as a cryterion to select patients eligible for progestinic therapy.
 ...
PMID:Steroid receptors and progestinic therapy in ovarian endometrioid carcinoma. 622 Sep 3

Ten advanced cancer patients not amendable to conventional therapy were treated with high dose (greater than 500 mg/day, for 30 days) Medroxyprogesterone Acetate (MAP) both orally and intramuscularly, in order to evaluate a possible anabolic effect of this hormone. During the treatment, mean protein intake increased from 37.2 gr/day to 58.8 gr/day (p less than 0.01), nitrogen intake from 5.8 to 9.4 gr/day (p less than 0.01) and caloric intake from 1407.9 to 2075 Kcal/day (p less than 0.01). Nitrogen balance also showed a significant increase (p less than 0.05), as well as elementary strength (p less than 0.02). Lean body mass and body weight did not show significant variations. The above data confirms what was already been documented by us in animals and proposed in man-that MAP has an anabolic effect.
 ...
PMID:The anabolic effect of high dose medroxyprogesterone acetate in oncology. 622 31

The "ram effect" (RE) is an inexpensive technique that allows farmers to obtain out-of-season lambs. Five hundred and ninety-six Corriedale ewes were used in three experiments to determine the effectiveness of different medroxyprogesterone (MAP) treatments associated with the ram effect during the nonbreeding season. The aim of the first experiment was to evaluate the effectiveness of short-term (6-day) MAP priming. We obtained similar results in estrus incidence and fertility after using MAP sponges for 6, 9, and 13 days. In the second experiment, we compared the effect of sponges containing 20, 40, or 60 mg of MAP used in 6-day priming. Estrous behavior and fertility were not affected by dosage. In the third experiment, 2.5mg of MAP was administered in single treatments 0, 1, 3, or 5 days before the introduction of the rams. Medroxyprogesterone administration 1, 3, or 5 days before the introduction of the rams concentrated estrus in ewes 17 to 20 days later.
 ...
PMID:Medroxyprogesterone priming and response to the ram effect in Corriedale ewes during the nonbreeding season. 1262 May 78